Experience
Regents of the Univ. of Cal.
Eli Lilly and Company
Finnegan successfully represented Eli Lilly in a litigation against Genentech and the Regents of the University of California (UC) regarding Eli Lilly’s Humulin® insulin product, the first biotechnology product to be marketed in the United States. We obtained judgment, affirmed on appeal, that UC’s patents were either not infringed or invalid under the written description requirement of 35 U.S.C. § 112.
Regents of the Univ. of Cal. v. Eli Lilly and Company, 92-cv-00224, S.D. Ind., Judges Dillin, Godich
Eli Lilly and Company v. Regents of the Univ. of Cal., 96-1175, Fed. Cir., Judges Newman, Lourie, Bryson
Eli Lilly and Co. v. Apotex Inc.
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
Eli Lilly and Company
Sun Pharmaceutical Inds. v. Eli Lilly and Co.
Eli Lilly and Company
Eli Lilly & Co. v. Wockhardt Ltd.
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Eli Lilly and Company v. Perrigo Co.
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.